What amount sold does Impact Proteomics, LLC report in Form D filings?

The latest linked filings report $250K sold across 2 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Impact Proteomics, LLC's most recent SEC filing?

Impact Proteomics, LLC's most recent Form D filing was on 2024-08-14.

How many investors does Impact Proteomics, LLC have?

The most recent Form D filing lists 1 investor(s).

Impact Proteomics, LLC

CIK: 0001804332·Biotechnology·PITTSBURGH, PA·Limited Liability Company

Reported Sold

$250,000

Total Filings

Identified Offerings

Last Filed

Aug 14, 2024

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Aug 14, 2024Form D — New notice

Reported sold: $50,000 · Target: $1,000,000

Rule 506(b)·1 investor

Feb 21, 2020Form D — New notice

Reported sold: $200,000 · Target: $300,000

Rule 506(b)·2 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

Latest reported sold across 2 identified offerings

$250,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Jonathan Minden

Related Person

Appears on 2 filings

Amber Lucas

Related Person

Appears on 1 filing

Jeffrey Whitmore

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Aug 14, 2024	New	$1,000,000	$50,000	1
Feb 21, 2020	New	$300,000	$200,000	2

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

511 Therapeutics, Inc.

Biotechnology

Offering target: $1,000,000

Filed Oct 30, 2026